• Je něco špatně v tomto záznamu ?

Multi-level disruption of the extrinsic apoptotic pathway mediates resistance of leukemia cells to TNF-related apoptosis-inducing ligand (TRAIL)

S. Leahomschi, J. Molinsky, M. Klanova, L. Andera, M. Peterka, Z. Gasova, P. Klener, M. Trneny, E. Necas, T. Simonova, J. Zivny, P. Klener,

. 2013 ; 60 (2) : 223-31.

Jazyk angličtina Země Slovensko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc13024050

Disruption of apoptotic pathways belongs to commonly reported molecular mechanisms that underlie cancer drug resistance. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL, Apo2L) is a cytokine of the TNF family with selective anti-tumor activity and minimal toxicity toward healthy tissues. Primary leukemia cells are, however, largely intrinsically resistant to TRAIL-induced apoptosis. In this study we analyzed molecular differences between TRAIL-resistant K562 cell line and TRAIL-sensitive K562 clones. We demonstrate that TRAIL-sensitive K562 cells differ from the TRAIL-resistant cell line by cell surface downregulation of TRAIL decoy receptor 1, upregulation of both TRAIL death receptors, enhanced assembly and improved functioning of the death-inducing signaling complex, and increased cytoplasmic protein expression of CASP8 and key proapoptotic BCL2 members BID, BIM, BAD and BAK. The molecular basis of the intrinsic leukemia cell TRAIL resistance thus appears a consequence of the multi-level disruption of the extrinsic apoptotic pathway. The results of this study also suggest that the leukemia TRAIL-resistance is functional, leaving a possibility of overcoming the resistance by preexposure of the leukemia cells to potent TRAIL sensitizers, e.g. BH3-mimetics.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13024050
003      
CZ-PrNML
005      
20130703125522.0
007      
ta
008      
130703s2013 xo f 000 0|eng||
009      
AR
024    7_
$a 10.4149/neo_2013_030 $2 doi
035    __
$a (PubMed)23259793
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xo
100    1_
$a Leahomschi, S $u Charles University, Prague, Czech Republic.
245    10
$a Multi-level disruption of the extrinsic apoptotic pathway mediates resistance of leukemia cells to TNF-related apoptosis-inducing ligand (TRAIL) / $c S. Leahomschi, J. Molinsky, M. Klanova, L. Andera, M. Peterka, Z. Gasova, P. Klener, M. Trneny, E. Necas, T. Simonova, J. Zivny, P. Klener,
520    9_
$a Disruption of apoptotic pathways belongs to commonly reported molecular mechanisms that underlie cancer drug resistance. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL, Apo2L) is a cytokine of the TNF family with selective anti-tumor activity and minimal toxicity toward healthy tissues. Primary leukemia cells are, however, largely intrinsically resistant to TRAIL-induced apoptosis. In this study we analyzed molecular differences between TRAIL-resistant K562 cell line and TRAIL-sensitive K562 clones. We demonstrate that TRAIL-sensitive K562 cells differ from the TRAIL-resistant cell line by cell surface downregulation of TRAIL decoy receptor 1, upregulation of both TRAIL death receptors, enhanced assembly and improved functioning of the death-inducing signaling complex, and increased cytoplasmic protein expression of CASP8 and key proapoptotic BCL2 members BID, BIM, BAD and BAK. The molecular basis of the intrinsic leukemia cell TRAIL resistance thus appears a consequence of the multi-level disruption of the extrinsic apoptotic pathway. The results of this study also suggest that the leukemia TRAIL-resistance is functional, leaving a possibility of overcoming the resistance by preexposure of the leukemia cells to potent TRAIL sensitizers, e.g. BH3-mimetics.
650    12
$a apoptóza $7 D017209
650    _2
$a chemorezistence $7 D019008
650    _2
$a lidé $7 D006801
650    _2
$a buňky K562 $7 D020014
650    _2
$a TRAIL receptory $x analýza $7 D053220
650    _2
$a signální transdukce $7 D015398
650    _2
$a protein TRAIL $x farmakologie $7 D053221
650    _2
$a TNF-alfa $x farmakologie $7 D014409
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Molinsky, J $u -
700    1_
$a Klanova, M $u -
700    1_
$a Andera, L $u - $7 gn_A_00006002
700    1_
$a Peterka, M $u -
700    1_
$a Gasova, Z $u -
700    1_
$a Klener, P $u -
700    1_
$a Trneny, M $u -
700    1_
$a Necas, E $u -
700    1_
$a Simonova, T $u -
700    1_
$a Zivny, J $u -
700    1_
$a Klener, P $u -
773    0_
$w MED00003470 $t Neoplasma $x 0028-2685 $g Roč. 60, č. 2 (2013), s. 223-31
856    41
$u https://pubmed.ncbi.nlm.nih.gov/23259793 $y Pubmed
910    __
$a ABA008 $b A 1194 $c 659 $y a $z 0
990    __
$a 20130703 $b ABA008
991    __
$a 20130703125939 $b ABA008
999    __
$a ok $b bmc $g 987730 $s 822430
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 60 $c 2 $d 223-31 $i 0028-2685 $m Neoplasma $n Neoplasma $x MED00003470
LZP    __
$a Pubmed-20130703

Najít záznam

Citační ukazatele

Možnosti archivace